Customize
Quick Links
Specialties

Physicians' Education Resource®, LLC, is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

Physicians' Education Resource®, LLC, designates this enduring material for a maximum of 1.5 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Acknowledgment of Commercial Support

This activity is supported by educational grants from Astellas, Bayer HealthCare Pharmaceuticals, Inc., and Medivation, Inc., a Pfizer Company.

Community Practice Connections™: Personalized Sequencing in Castration-Resistant Prostate Cancer: Bridging the Latest Evidence to the Bedside in Clinical Management

Release Date: August 31, 2017
Expiration Date: August 31, 2018
Media: Internet - based

 

Activity Overview

Community Practice Connections™: Personalized Sequencing in Castration-Resistant Prostate Cancer: Bridging the Latest Evidence to the Bedside in Clinical Management provides clinicians with an in-depth exploration of several clinical scenarios involving patients with metastatic prostate cancer, as well as a review of the latest literature that may help to guide treatment approaches for these patients. The text is accompanied by video interviews of leading experts in the treatment of patients with prostate cancer, who address questions commonly faced in the community oncology practice setting and provide their perspectives on recent data.

Acknowledgment of Commercial Support

This activity is supported by educational grants from Astellas, Bayer HealthCare Pharmaceuticals, Inc., and Medivation, Inc., a Pfizer Company.

Instructions for This Activity and Receiving Credit

  • You will need to login to participate in the activity.
  • Each presentation may contain an interactive question(s). You may move forward through the presentation; however, you may not go back to change answers or review videos/content until you finish the presentation.
  • At the end of the activity, “educational content/video files” will be available for your reference.
  • In order to receive a cme certificate, participants must complete the activity.
  • Complete the posttest and pass with a score of 70% or higher, complete the evaluation and then click on request for credit. Participants may immediately download a cme certificate upon completion of these steps.

Target Audience

This educational activity is directed toward community-based medical oncologists, surgical oncologists, and radiation oncologists interested in the treatment of CRPC. Nurse practitioners, physician assistants, nurses, and other healthcare professionals involved in the treatment and management of patients with CRPC also are invited to participate.

Learning Objectives

At the conclusion of this activity, you should be better prepared to:

  1. Describe how risk stratification and tumor information can guide sequencing in the management of castration-resistant prostate cancer (CRPC)
  2. Develop strategies to manage treatment-related side effects in patients with CRPC
  3. Evaluate recent practice-changing clinical trial findings concerning novel compounds or strategies to manage CRPC, including chemotherapeutic, hormonal, immunotherapeutic, and bone-directed approaches
  4. Apply emerging clinical concepts to create personalized treatment plans for the care of patients with CRPC

Faculty, Staff, and Planners' Disclosures

Faculty

Tomasz M. Beer, MD, FACP
Deputy Director, OHSU Knight Cancer Institute
Grover C. Bagby Endowed Chair for Prostate Cancer Research
Oregon Health & Science University
Portland, OR

Disclosure: Grant/Research Support: Astellas Pharma, Boehringer Ingelheim, Bristol-Myers Squibb, Dendreon, Janssen, Medivation, OncoGeneX, Sotio; Consultant: Janssen Japan

Celestia S. Higano, MD, FACP
Professor, Medicine and Urology
University of Washington
Member, Fred Hutchinson Cancer Research Center
Seattle, WA
 

Disclosure: Grant/Research Support: Medivation, Dendreon, Genentech Aragon Pharmaceuticals, Astra Zeneca AB, Bayer HealthCare, Aptevo Therapeutics (Emergent BioSolutions), Pfizer; Consultant: Bayer HealthCare, Dendreon, Genentech, Ferring, Orion, Pfizer Inc., Blue Earth Diagnostics, Asana BioSciences, Endocyte, Clovis Oncology; Other: Spouse is in leadership role at CTI Biopharma

Howard I. Scher, MD
D Wayne Calloway Chair in Urologic Oncology
Chief, Genitourinary Oncology Service
Memorial Sloan Kettering Cancer Center
Professor of Medicine
Weill Cornell Medical College
New York, NY

Disclosure: Grant/Research Support: Research funding for Memorial Sloan Kettering Cancer Center from: Illumina, Inc., Innocrin Pharma, Janssen Diagnostics, Janssen, Pharmaceuticals, Medivation; Consultant: Clovis Oncology, Ferring Pharmaceuticals (Uncompensated), Janssen Research & Development (Uncompensated), LLC, Merck, Sanofi Aventis, WCG Oncology; Shareholder: Asterias Biotherapeutics (stock options); Other: Asterias Biotherapeutics (Leadership - Board of Directors)

Guru P. Sonpavde, MD
Associate Professor of Medicine
Director, Urologic Malignancies
The University of Alabama at Birmingham (UAB) School of Medicine
Birmingham, AL

Disclosure: Grant/Research Support: Boehringer-Ingelheim, Bayer, Onyx-Amgen, Pfizer, Merck, Celgene; Consultant: Pfizer, Genentech, Novartis, Argos, Merck, Sanofi, Agensys, Astra Zeneca, Exelixis, Bristol-Myers Squibb, Janssen, Amgen, Eisai; Speakers Bureau: NCCN, Clinical Care Options; Other: Author for UptoDate.

The staff of PER® have no relevant financial relationships with commercial interests to disclose.

Disclosure Policy and Resolution of Conflicts of Interest (COI)

As a sponsor accredited by the ACCME, it is the policy of PER® to ensure fair balance, independence, objectivity, and scientific rigor in all of its cme activities. In compliance with ACCME guidelines, PER® requires everyone who is in a position to control the content of a cme activity to disclose all relevant financial relationships with commercial interests. The ACCME defines “relevant financial relationships” as financial relationships in any amount occurring within the past 12 months that creates a COI.

Additionally, PER® is required by ACCME to resolve all COI. PER® has identified and resolved all COI prior to the start of this activity by using a multistep process.

Off-Label Disclosure and Disclaimer

This cme activity may or may not discuss investigational, unapproved, or off-label use of drugs. Participants are advised to consult prescribing information for any products discussed. The information provided in this cme activity is for continuing medical and nursing education purposes only, and is not meant to substitute for the independent clinical judgment of a physician relative to diagnostic, treatment, or management options for a specific patient’s medical condition. The opinions expressed in the content are solely those of the individual faculty members and do not reflect those of PER®.

CME Provider Contact Information

Physicians’ Education Resource®, LLC
2 Clarke Drive
Suite 110
Cranbury, NJ 08512
info@gotoper.com

Hardware And Software Requirements 

Supported Browsers
Internet Explorer v.7 or greater (for Windows) | Mozilla Firefox v.2 or greater (for Windows, Mac, Linux)

Minimum System Requirements (Windows)

  • A Pentium-based PC or compatible computer
  • At least 64MB of RAM
  • Windows 95/98/NT/ME/2000/XP/Vista system software
  • Screen resolution of 1024 x 786 or larger recommended
  • PDF Reader: Adobe Reader 5.0 or higher, Foxit Reader 2.0 or likewise

Minimum System Requirements (Mac OS)

  • A PowerPC processor-based Macintosh computer
  • At least 64MB of RAM
  • Mac OS 7.5 or later
  • Screen resolution of 1024 x 786 or larger recommended
  • PDF Reader: Adobe Reader 5.0 or higher, Foxit Reader 2.0 or likewise






Become a Member

Forgot Password?
Calendar of Events
SUNMONTUESWEDTHURSFRISAT
     12
3456789
10111213141516
17181920212223
24252627282930
31
Filter By